Exelixis, Inc. (EXEL)
54.62
+0.17
(+0.31%)
USD |
NASDAQ |
Aug 31, 16:00
54.70
+0.08
(+0.15%)
After-Hours: 17:41
Exelixis Research and Development Expense (Annual) : 825.00M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 825.00M |
| December 31, 2024 | 910.41M |
| December 31, 2023 | 1.044B |
| December 31, 2022 | 891.81M |
| December 31, 2021 | 693.72M |
| December 31, 2020 | 547.85M |
| December 31, 2019 | 336.96M |
| December 31, 2018 | 182.26M |
| December 31, 2017 | 112.17M |
| December 31, 2016 | 95.97M |
| December 31, 2015 | 96.35M |
| December 31, 2014 | 189.10M |
| December 31, 2013 | 178.76M |
| Date | Value |
|---|---|
| December 31, 2012 | 128.88M |
| December 31, 2011 | 156.84M |
| December 31, 2010 | 210.68M |
| December 31, 2009 | 234.70M |
| December 31, 2008 | 257.39M |
| December 31, 2007 | 225.38M |
| December 31, 2006 | 185.48M |
| December 31, 2005 | 141.14M |
| December 31, 2004 | 137.72M |
| December 31, 2003 | 127.62M |
| December 31, 2002 | 95.98M |
| December 31, 2001 | 72.58M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| BioMarin Pharmaceutical, Inc. | 700.97M |
| Cytokinetics, Inc. | 405.90M |
| Emergent BioSolutions, Inc. | 53.80M |
| Gilead Sciences, Inc. | 5.688B |